Literature DB >> 27815446

Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning.

Antonia M S Müller1,2, Mareike Florek3, Holbrook E K Kohrt4, Natascha J Küpper3, Alexander Filatenkov5, Jessica A Linderman3, Husein Hadeiba6, Robert S Negrin3, Judith A Shizuru1.   

Abstract

T cells are widely used to promote engraftment of hematopoietic stem cells (HSCs) during an allogeneic hematopoietic cell transplantation. Their role in overcoming barriers to HSC engraftment is thought to be particularly critical when patients receive reduced doses of preparative chemotherapy and/or radiation compared with standard transplantations. In this study, we sought to delineate the effects CD4+ cells on engraftment and blood formation in a model that simulates clinical hematopoietic cell transplantation by transplanting MHC-matched, minor histocompatibility-mismatched grafts composed of purified HSCs, HSCs plus bulk T cells, or HSCs plus T cell subsets into mice conditioned with low-dose irradiation. Grafts containing conventional CD4+ T cells caused marrow inflammation and inhibited HSC engraftment and blood formation. Posttransplantation, the marrows of HSCs plus CD4+ cell recipients contained IL-12-secreting CD11c+ cells and IFN-γ-expressing donor Th1 cells. In this setting, host HSCs arrested at the short-term stem cell stage and remained in the marrow in a quiescent cell cycling state (G0). As a consequence, donor HSCs failed to engraft and hematopoiesis was suppressed. Our data show that Th1 cells included in a hematopoietic allograft can negatively impact HSC activity, blood reconstitution, and engraftment of donor HSCs. This potential negative effect of donor T cells is not considered in clinical transplantation in which bulk T cells are transplanted. Our findings shed new light on the effects of CD4+ T cells on HSC biology and are applicable to other pathogenic states in which immune activation in the bone marrow occurs such as aplastic anemia and certain infectious conditions.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27815446      PMCID: PMC5096509          DOI: 10.4049/jimmunol.1500715

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

Review 1.  Immunosuppressive therapies in the management of acquired immune-mediated marrow failures.

Authors:  Antonio M Risitano
Journal:  Curr Opin Hematol       Date:  2012-01       Impact factor: 3.284

2.  Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues.

Authors:  Steffen Massberg; Patrick Schaerli; Irina Knezevic-Maramica; Maria Köllnberger; Noah Tubo; E Ashley Moseman; Ines V Huff; Tobias Junt; Amy J Wagers; Irina B Mazo; Ulrich H von Andrian
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

3.  Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair.

Authors:  Anne Wilson; Elisa Laurenti; Gabriela Oser; Richard C van der Wath; William Blanco-Bose; Maike Jaworski; Sandra Offner; Cyrille F Dunant; Leonid Eshkind; Ernesto Bockamp; Pietro Lió; H Robson Macdonald; Andreas Trumpp
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

4.  Aplastic anaemia in sublethally irradiated mice given allogeneic lymph node cells.

Authors:  D W Barnes; R H Mole
Journal:  Br J Haematol       Date:  1967-07       Impact factor: 6.998

5.  T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin.

Authors:  Ann A Jakubowski; Trudy N Small; James W Young; Nancy A Kernan; Hugo Castro-Malaspina; Katherine C Hsu; Miguel-Angel Perales; Nancy Collins; Christine Cisek; Michelle Chiu; Marcel R M van den Brink; Richard J O'Reilly; Esperanza B Papadopoulos
Journal:  Blood       Date:  2007-08-23       Impact factor: 22.113

6.  The effect of bleeding on hematopoietic stem cell cycling and self-renewal.

Authors:  Samuel H Cheshier; Susan S Prohaska; Irving L Weissman
Journal:  Stem Cells Dev       Date:  2007-10       Impact factor: 3.272

7.  IFNalpha activates dormant haematopoietic stem cells in vivo.

Authors:  Marieke A G Essers; Sandra Offner; William E Blanco-Bose; Zoe Waibler; Ulrich Kalinke; Michel A Duchosal; Andreas Trumpp
Journal:  Nature       Date:  2009-02-11       Impact factor: 49.962

8.  Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection.

Authors:  Megan T Baldridge; Katherine Y King; Nathan C Boles; David C Weksberg; Margaret A Goodell
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

9.  Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro.

Authors:  J Maciejewski; C Selleri; S Anderson; N S Young
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

10.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.

Authors:  Norbert Frickhofen; Hermann Heimpel; Joachim P Kaltwasser; Hubert Schrezenmeier
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

View more
  2 in total

1.  siRNA against CD40 delivered via a fungal recognition receptor ameliorates murine acute graft-versus-host disease.

Authors:  Beate Heissig; Yousef Salama; Masatoshi Tateno; Satoshi Takahashi; Koichi Hattori
Journal:  EJHaem       Date:  2022-05-06

Review 2.  Harnessing invariant natural killer T cells to control pathological inflammation.

Authors:  Nikhila S Bharadwaj; Jenny E Gumperz
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.